Better Therapeutics, Inc.

OTC: BTTX · Healthcare · Biotechnology

PublicHQ San Francisco, CA · San FranciscoCIK 0001832415Reports USD

#1136 of 1,417 Healthcare companies by revenue

EA Score

——

FH —DQ 33GM —SS 26

v0.1 · 25/100 weight · pillars only

↑ filing timeliness, workforce scale · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$39.8M

Employees

as of 2026-07-12

Market cap

$5.5k

as of 2026-07-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$8.0k$8.0k2021

Net income-$39.8M-$39.8M2022

Operating income-$38.3M-$38.3M2022

Total assets$22.9M$22.9M2022

Liabilities$23.8M$23.8M2022

Equity-$899.0k-$899.0k2022

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Better Therapeutics, Inc.’s revenue?

Better Therapeutics, Inc. booked $8.0k in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -497000.0% net margin.

Peers · Healthcare

Modern Mobility Aids, Inc.——Voyageur Pharmaceuticals Ltd.——Genelux Corporation32D Kaya Holdings, Inc.——Aspire Biopharma Holdings, Inc.17D Creative Medical Technology Holdings, Inc.46D

Neighbors

San Francisco →

Visa Inc.$40.0B86A Wells Fargo & Company$85.1B55C Salesforce, Inc.$41.5B80B+Uber Technologies, Inc.$52.0B71B Prologis, Inc.$8.8B66B Cloudflare, Inc.$2.2B59C

Key facts

CEOCraig R. Jalbert

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Francisco, CA

ExchangeOTC: BTTX

Employees54

IPO date2021-10-29

Latest filings

8-K2024-03-21 8-K2024-03-15 8-K2024-03-14 8-K2024-03-11 8-K2024-03-04 8-K2024-01-08 8-K2023-12-18 8-K2023-12-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.